39 related articles for article (PubMed ID: 35333412)
1. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.
Allenson K; Castillo J; San Lucas FA; Scelo G; Kim DU; Bernard V; Davis G; Kumar T; Katz M; Overman MJ; Foretova L; Fabianova E; Holcatova I; Janout V; Meric-Bernstam F; Gascoyne P; Wistuba I; Varadhachary G; Brennan P; Hanash S; Li D; Maitra A; Alvarez H
Ann Oncol; 2017 Apr; 28(4):741-747. PubMed ID: 28104621
[TBL] [Abstract][Full Text] [Related]
2. Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells.
Wang S; Zhang X; Zou X; Wen M; Gan C; Jiang X; Li M; Shen R; Zhu D; Yao A; Fang Y; Fox BA; Hu HM; Yu G; Wang X
Cancer Immunol Immunother; 2023 May; 72(5):1301-1313. PubMed ID: 36436020
[TBL] [Abstract][Full Text] [Related]
3. Combination of mutations in genes controlling DNA repair and high mutational load plays a prognostic role in pancreatic ductal adenocarcinoma (PDAC): a retrospective real-life study in Sardinian population.
Sini MC; Doro MG; Frogheri L; Zinellu A; Paliogiannis P; Porcu A; Scognamillo F; Delogu D; Santeufemia DA; Persico I; Palomba G; Maestrale GB; Cossu A; Palmieri G
J Transl Med; 2024 Jan; 22(1):108. PubMed ID: 38280995
[TBL] [Abstract][Full Text] [Related]
4. Secreted frizzled related-protein 2 is prognostic for human pancreatic cancer patient survival and is associated with fibrosis.
Siegel JB; Nasarre P; Hsu L; Mukherjee R; Gormley M; Richardson B; Khan I; Morningstar JE; Hilliard E; O'Bryan JP; Helke KL; Spruill L; Dolloff NG; Klauber-DeMore N
Cancer Biomark; 2023; 38(3):287-300. PubMed ID: 37955079
[TBL] [Abstract][Full Text] [Related]
5. Genetic Signature of Human Pancreatic Cancer and Personalized Targeting.
Reshkin SJ; Cardone RA; Koltai T
Cells; 2024 Mar; 13(7):. PubMed ID: 38607041
[TBL] [Abstract][Full Text] [Related]
6. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.
Pant S; Wainberg ZA; Weekes CD; Furqan M; Kasi PM; Devoe CE; Leal AD; Chung V; Basturk O; VanWyk H; Tavares AM; Seenappa LM; Perry JR; Kheoh T; McNeil LK; Welkowsky E; DeMuth PC; Haqq CM; O'Reilly EM
Nat Med; 2024 Feb; 30(2):531-542. PubMed ID: 38195752
[TBL] [Abstract][Full Text] [Related]
7. Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations.
Linette GP; Bear AS; Carreno BM
Clin Cancer Res; 2024 May; 30(10):2017-2024. PubMed ID: 38266167
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal Adenocarcinoma.
Nusrat F; Khanna A; Jain A; Jiang W; Lavu H; Yeo CJ; Bowne W; Nevler A
J Clin Med; 2024 Apr; 13(7):. PubMed ID: 38610868
[TBL] [Abstract][Full Text] [Related]
9. Rim enhancement of pancreatic ductal adenocarcinoma: investigating the relationship with DCE-MRI-based radiomics and next-generation sequencing.
Choi MH; Yoon SB; Lee YJ; Jung ES; Pak S; Han D; Nickel D
Front Oncol; 2024; 14():1304187. PubMed ID: 38525415
[TBL] [Abstract][Full Text] [Related]
10. Targeting KRAS in PDAC: A New Way to Cure It?
He Q; Liu Z; Wang J
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291766
[TBL] [Abstract][Full Text] [Related]
11. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
12. Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma.
Huang J; Löhr JM; Nilsson M; Segersvärd R; Matsson H; Verbeke C; Heuchel R; Kere J; Iafrate AJ; Zheng Z; Ye W
Clin Chem; 2015 Nov; 61(11):1408-16. PubMed ID: 26378065
[TBL] [Abstract][Full Text] [Related]
13. Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
Alqahtani A; Alloghbi A; Coffin P; Yin C; Mukherji R; Weinberg BA
Surg Oncol; 2023 Dec; 51():102007. PubMed ID: 37852124
[TBL] [Abstract][Full Text] [Related]
14. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
15. KRAS mutation allele frequency threshold alters prognosis in right-sided resected pancreatic cancer.
Nauheim D; Moskal D; Renslo B; Chadwick M; Jiang W; Yeo CJ; Nevler A; Bowne W; Lavu H
J Surg Oncol; 2022 Aug; 126(2):314-321. PubMed ID: 35333412
[TBL] [Abstract][Full Text] [Related]
16. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
